Eosinophilic Esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus that can cause difficulty swallowing, chest pain, and food impactions. Biologics are a type of medication that target specific proteins in the immune system to help control the inflammation associated with EoE. Here are the top 5 biologics commonly used to treat EoE:
- Dupilumab (Dupixent): Dupilumab is a monoclonal antibody that targets interleukin-4 and interleukin-13, two proteins involved in the inflammatory response. It has been shown to significantly reduce eosinophilic inflammation in the esophagus and improve symptoms in patients with EoE.
- Reslizumab (Cinqair): Reslizumab is an anti-IL-5 monoclonal antibody that helps reduce the number of eosinophils, a type of white blood cell, in the esophagus. It has been shown to improve symptoms and reduce inflammation in patients with EoE.
- Mepolizumab (Nucala): Mepolizumab is another anti-IL-5 monoclonal antibody that works by targeting eosinophils in the esophagus. It has been shown to reduce eosinophilic inflammation and improve symptoms in patients with EoE.
- Budesonide (Uceris): Budesonide is a corticosteroid medication that can be used topically in the esophagus to reduce inflammation. It is often used as a first-line treatment for EoE and has been shown to be effective in controlling symptoms and improving esophageal inflammation.
- Benralizumab (Fasenra): Benralizumab is a monoclonal antibody that targets the IL-5 receptor on eosinophils, leading to their depletion. It has been shown to reduce eosinophilic inflammation and improve symptoms in patients with EoE.
It is important to consult with a healthcare provider to determine the most appropriate biologic treatment for EoE based on individual symptoms and medical history.